Integration of immunotherapy with radiotherapy in head-and-neck cancer: Synergy or sequencing?
The benefit of combining immunotherapy with radiotherapy in HNSCC lies with postoperative chemoradiation patients, not those treated with concurrent chemoradiation for unresectable disease — and progress in unresectable disease will likely depend on biomarker-driven selection and smarter sequencing rather than layering...